enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 40.39M | 33.83M | 30.98M | 28.69M | 27.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.65M | 132.58M | 127.74M | 123.17M | 101.14M |
| Operating Income | -136.65M | -132.58M | -127.74M | -123.17M | -101.14M |
| Income Before Tax | -130.86M | -127.11M | -122.46M | -117.30M | -94.21M |
| Income Tax Expenses | -497.00K | -258.00K | -18.00K | 0.00 | 516.00K |
| Earnings from Continuing Operations | -130.36 | -126.85 | -122.44 | -117.30 | -94.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.36M | -126.85M | -122.44M | -117.30M | -94.72M |
| EBIT | -136.65M | -132.58M | -127.74M | -123.17M | -101.14M |
| EBITDA | -135.93M | -131.91M | -127.14M | -122.66M | -100.72M |
| EPS Basic | -2.08 | -2.18 | -2.25 | -2.29 | -1.90 |
| Normalized Basic EPS | -1.30 | -1.36 | -1.40 | -1.43 | -1.18 |
| EPS Diluted | -2.08 | -2.18 | -2.25 | -2.29 | -1.90 |
| Normalized Diluted EPS | -1.30 | -1.36 | -1.40 | -1.43 | -1.18 |
| Average Basic Shares Outstanding | 258.11M | 239.47M | 220.76M | 204.48M | 197.53M |
| Average Diluted Shares Outstanding | 258.11M | 239.47M | 220.76M | 204.48M | 197.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |